PP
IDXG

Paloma Partners’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Paloma Partners’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-436
Closed -$205K – 1292
2013
Q2 		$205K Buy
+436
New +$198K 0.01% 915

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KSC
Kendall Square Capital San Francisco, California $4.92M AUM 2.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
LCM
Leonard Capital Management Vero Beach, Florida $5.25M AUM

Paloma Partners's IDXG Position: Q3 2013 in Review

Paloma Partners sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q3 2013, closing a stake of 436 shares — an estimated $205K sold.

Paloma Partners first reported a position in IDXG in Q2 2013 and held it in 1 quarter. The position peaked at $205K in Q2 2013. 29 funds tracked by Wall St. Rank hold IDXG as of Q3 2013.

  • Paloma Partners reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • Paloma Partners sold 436 Interpace Biosciences, Inc. Common Stock shares in Q3 2013, an estimated $205K.
  • Paloma Partners first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • Paloma Partners's Interpace Biosciences, Inc. Common Stock position peaked at $205K in Q2 2013.
  • 29 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q3 2013.

Based on Paloma Partners's 13F filing for Q3 2013, filed 14 Nov 2013.